Data gathered: October 3
Alternative Data for Halozyme Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 86 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 26 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,822 | Sign up | Sign up | Sign up |
| Twitter Followers | 642 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| X Mentions | 17 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 65 | Sign up | Sign up | Sign up |
| Linkedin Employees | 469 | Sign up | Sign up | Sign up |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
| Price | $68.98 |
| Target Price | Sign up |
| Volume | 2,660,000 |
| Market Cap | $8.77B |
| Year Range | $47.91 - $78.28 |
| Dividend Yield | 0% |
| PE Ratio | 16.88 |
| Analyst Rating | 43% buy |
| Industry | Biotechnology |
In the news
 |
Benchmark Sees More Upside for Halozyme Therapeutics (HALO), Hikes Price TargetOctober 1 - Yahoo |
 |
Halozyme Therapeutics, Inc. $HALO Shares Acquired by State of Alaska Department of RevenueOctober 1 - ETF Daily News |
 |
Halozyme Therapeutics, Inc. (HALO) M&A Call TranscriptOctober 1 - SeekingAlpha |
|
Halozyme Therapeutics, Inc. $HALO Holdings Cut by Fifth Third BancorpOctober 1 - ETF Daily News |
|
Halozyme Therapeutics, Inc. (HALO) Elektrofi, Inc., M&A Call - SlideshowSeptember 30 - SeekingAlpha |
|
Halozyme Therapeutics (NASDAQ:HALO) Given New $90.00 Price Target at BenchmarkSeptember 25 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 326M | 46M | 279M | 165M | 230M | 1.540 |
| Q1 '25 | 265M | 48M | 216M | 118M | 169M | 1.110 |
| Q4 '24 | 298M | 42M | 256M | 137M | 203M | 1.260 |
| Q3 '24 | 290M | 49M | 241M | 137M | 190M | 1.270 |
| Q2 '24 | 231M | 57M | 174M | 93M | 138M | 0.910 |
Insider Transactions View All
| Connaughton Bernadette filed to sell 44,952 shares at $75.7. October 1 '25 |
| Connaughton Bernadette filed to sell 45,452 shares at $75.1. October 1 '25 |
| LaBrosse Nicole filed to sell 22,079 shares at $78.7. September 23 '25 |
| LaBrosse Nicole filed to sell 22,393 shares at $77.8. September 23 '25 |
| LaBrosse Nicole filed to sell 37,546 shares at $75.3. September 11 '25 |
Similar companies
Read more about Halozyme Therapeutics (HALO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Halozyme Therapeutics?
The Market Cap of Halozyme Therapeutics is $8.77B.
What is Halozyme Therapeutics' PE Ratio?
As of today, Halozyme Therapeutics' PE (Price to Earnings) ratio is 16.88.
What is the current stock price of Halozyme Therapeutics?
Currently, the price of one share of Halozyme Therapeutics stock is $68.98.
How can I analyze the HALO stock price chart for investment decisions?
The HALO stock price chart above provides a comprehensive visual representation of Halozyme Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Halozyme Therapeutics shares. Our platform offers an up-to-date HALO stock price chart, along with technical data analysis and alternative data insights.
Does HALO offer dividends to its shareholders?
As of our latest update, Halozyme Therapeutics (HALO) does not offer dividends to its shareholders. Investors interested in Halozyme Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Halozyme Therapeutics?
Some of the similar stocks of Halozyme Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.